Prulifloxacin: a new antibacterial fluoroquinolone

References

• Brighty KE, Gootz TD. Chemistry and mechanism of action of the quinolones antibacterials. In: The Quinolones, Third Edition. Andriole VT (Ed.). Academic Press, CA, USA, 33–97 (2000).
   Google Scholar
• Yao JDC, Moellering RC. Antibacterial agents. In: Manual of Clinical Microbiology, Eighth Edition. Murray PR (Ed.). ASM Press, Washington DC, USA, 1039–1073 (2003).
   Google Scholar
• Andriole VT. The quinolones: past, present, and future. Clin. Infect. Dis. 41(Suppl. 2), S113–S119 (2005).
   PubMed Web of Science ®Google Scholar
• Lescher GY, Forelich EJ, Gruett MD, Bailey JH, Brundage RP. 1,8-naphthyridine derivatives: a new class of chemotherapeutic agents. J. Med. Pharm. Chem. 91, 1063–1065 (1962).
   PubMedGoogle Scholar
• Ball P. Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother. 46(Suppl. T1), 17–24 (2000).
   PubMed Web of Science ®Google Scholar
• Andersson M, MacGowan AP. Development of the quinolones. J. Antimicrob. Chemother. 51(Suppl. 1), 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Zufiaurre N. Relación entre estructura, actividad y efectos adversos de las quinolonas. Rev. Esp. Quimioter. 17, 232–243 (2004).
   PubMedGoogle Scholar
• Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 41(Suppl. 2), 127–135 (2005).
   PubMed Web of Science ®Google Scholar
• Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis. 41(Suppl. 2), S144–S157 (2005).
   PubMed Web of Science ®Google Scholar
• Domagala JM. Structure–activity and structure–side effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33(4), 685–706 (1994).
   PubMed Web of Science ®Google Scholar
• Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 21(3), 301–319 (2001).
   PubMed Web of Science ®Google Scholar
• van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch. Intern. Med. 163(15), 1801–1807 (2003).
   PubMed Web of Science ®Google Scholar
• Jacoby GA. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41(Suppl. 2), S120–S126 (2005).
   PubMed Web of Science ®Google Scholar
• Li XZ. Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms. Int. J. Antimicrob. Agents 25(6), 453–463 (2005).
   PubMedGoogle Scholar
• Mammeri H, Van De Loo M, Poirel L, Martínez-Martínez L, Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob. Agents Chemother. 49(1), 71–76 (2005).
   PubMed Web of Science ®Google Scholar
• Rice LB, Sahm D, Bonomo RA. Mechanisms of resistance to antibacterial agents. In: Manual of Clinical Microbiology, Eighth Edition. Murray PR (Ed.). ASM Press, Washington DC, USA, 1074–1101 (2003).
   Google Scholar
• Ozaki M, Matsuda M, Tomii Y et al. In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob. Agents Chemother. 35(12), 2496–2499 (1991). Erratum in: Antimicrob. Agents Chemother. 36, 1170 (1992), Antimicrob. Agents Chemother. 37, 930 (1993).
   PubMedGoogle Scholar
• Tougou K, Nakamura A, Watanabe S, Okuyama Y, Morino A. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab. Dispos. 26(4), 355–359 (1998).
   PubMed Web of Science ®Google Scholar
• Keam SJ, Perry CM. Prulifloxacin. Drugs 64, 2221–2234 (2004).
   PubMed Web of Science ®Google Scholar
• Ozaki M, Matsuda M, Tomii Y et al. In vitro antibacterial activity of a new quinolone, NM394. Antimicrob. Agents Chemother. 35, 2490–2495 (1991). Erratum in: Antimicrob. Agents Chemother. 36, 1170 (1992).
   PubMed Web of Science ®Google Scholar
• Alovero FL, Pan XS, Morris JE, Manzo RH, Fisher LM. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob. Agents Chemother. 44, 320–325 (2000).
   PubMed Web of Science ®Google Scholar
• Bryskier A, Chantot JF. Classification and structure–activity relationships of fluoroquinolones. Drugs 49(Suppl. 2), 16–28 (1995).
   PubMedGoogle Scholar
• Peterson LR. Quinolone molecular structure–activity relationships: what we have learned about improving antimicrobial activity. Clin. Infect. Dis. 33(Suppl. 3), S180–S186 (2001).
   PubMed Web of Science ®Google Scholar
• Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42, 2810–2816 (1998).
   PubMed Web of Science ®Google Scholar
• Blanche F, Cameron B, Bernard FX et al. Differential behaviors of Staphylococcus aureus and Escherichia coli Type II DNA topoisomerase. Antimicrob. Agents Chemother. 40, 2714–2720 (1996).
   PubMed Web of Science ®Google Scholar
• Kishii R, Takei M, Fukuda H, Hayashi K, Hosaka M. Contribution of the 8-metoxy group to the activity of gatifloxacin against Type II topoisomerase of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47, 77–81 (2003).
   PubMed Web of Science ®Google Scholar
• Tani M, Maebashi K, Araake M, Watabe H. Inhibitory activity of NM394, the active form of prodrug prulifloxacin against Type II topoisomerase from Pseudomonas aeruginosa. Jpn. J. Antibiot. 55, 882–885 (2002).
   PubMedGoogle Scholar
• Yoshida T, Mitsuhashi S. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob. Agents Chemother. 37, 793–800 (1993).
   PubMed Web of Science ®Google Scholar
• Prats G, Roig C, Miró E, Navarro F, Mirelis B. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur. J. Clin. Microbiol. Infect. Dis. 21, 328–334 (2002). Erratum in: Eur. J. Clin. Microbiol. Infect. Dis. 23, 422 (2004).
   PubMed Web of Science ®Google Scholar
• Montanari MP, Mingoia M, Varaldo PE. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob. Agents Chemother. 45, 3616–3622 (2001).
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement. Approved standard M100-S9. NCCLS, PA, USA (1999).
   Google Scholar
• Montanari MP, Ferrante L, Tili E, Cochetti I, Rossi V, Varaldo PE. Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin. J. Chemother. 17, 138–142 (2005).
   PubMed Web of Science ®Google Scholar
• Saito A, Inamatsu T, Okada J et al. Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released. J. Infect. Chemother. 5, 223–226 (1999).
   PubMedGoogle Scholar
• Okuyama Y, Momota K, Morino A. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. Arzneimittelforschung 47, 276–284 (1997).
   PubMedGoogle Scholar
• Okuyama Y, Momota K, Morino A. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats. Arzneimittelforschung 47, 285–292 (1997).
   PubMedGoogle Scholar
• Angelini. ACRAF SPA Investigator’s brochure: Unidrox® prulifloxacin 600 mg tablets. ACRAF SPA, Rome, Italy, April 20 (2004) (Data on file).
   Google Scholar
• Nakashima M, Uematsu Y, Kosuge K et al. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J. Clin. Pharmacol. 34, 930–937 (1994).
   PubMed Web of Science ®Google Scholar
• Picollo R, Brion N, Gualano V et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 53, 201–205 (2003).
   PubMed Web of Science ®Google Scholar
• Mikamo H, Kawazoe K, Izumi K, Ito K, Tamaya T. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients. Drugs 49(Suppl. 2), 326–330 (1995).
   PubMedGoogle Scholar
• Villa G, Olivieri L, Picollo R, Dionisio P. Safety, tolerability and pharmacokinetic evaluation of prulifloxacin (AF3012) 600 mg single dose in patients with mild or moderate renal impairment. Angelini Ricerche SPA, Rome, Italy, Aug 28 (1998) (Data on file).
   Google Scholar
• Ozaki M, Komori K, Matsuda M et al. Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 40, 739–742 (1996).
   PubMedGoogle Scholar
• Tullio V, Cuffini AM, Bonino A, Ianni Palarchio A, Rossi V, Carlone NA. Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae. Drugs Exp. Clin. Res. 25, 1–11 (1999).
   PubMedGoogle Scholar
• Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin. Ther. 22(7), 798–817 (2000).
   PubMed Web of Science ®Google Scholar
• Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin. Ther. 21(1), 3–40 (1999).
   PubMed Web of Science ®Google Scholar
• Ball P. Future of the quinolones. Semin. Respir. Infect. 16(3), 215–224 (2001).
   PubMedGoogle Scholar
• Lacroix P, Crumb WJ, Durando L, Ciottoli GB. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur. J. Pharmacol. 477(1), 69–72 (2003).
   PubMed Web of Science ®Google Scholar
• Akita M, Shibazaki Y, Izumi M et al. Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J. Toxicol. Sci. 29, 63–71 (2004).
   PubMedGoogle Scholar
• Shiba K, Yoshida M, Sakay, Saito A. Pharmacokinetics and clinical studies on NM441. Jpn J. Chemother. 44(Suppl. 1), 263–278 (1996).
   Google Scholar
• Fattore G, Cipolla G, Gatti G et al. Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers. Clin. Drug Invest. 16, 387–392 (1998).
   Web of Science ®Google Scholar
• Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51, 1019–1074 (1996).
   PubMed Web of Science ®Google Scholar
• Cervigni M, Orticelli G, Bologna M et al. Single-dose prulifloxacin versus single-dose pefloxacin in the treatment of acute uncomplicated urinary tract infection in women. Urogynaecol. Int. 17, 69–77 (2003).
   Google Scholar
• Zagni R, Orticelli G, Rosignoli MT, Dionisio P. Double-bind, controlled study of prulifloxacin in comparison with ciprofloxacin in the treatment of acute uncomplicated lower urinary tract infections. Angelini Ricerche SPA, Rome, Italy, June 27 (1998) (Data on file).
   Google Scholar
• Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol. Int. 74(4), 326–331 (2005).
   PubMed Web of Science ®Google Scholar
• Defidio L, Olivieri L, Rosignoli MT, Dionisio P. Efficacy and tolerability of prulifloxacin versus amoxi-clavulanic acid in the treatment of complicated urinary tract infections. Angelini Ricerche SPA, Rome, Italy, May 27 (1998) (Data on file).
   Google Scholar
• Grassi C, Salvatori E, Rosignoli MT, Dionisio P, Prulifloxacin Study Group. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 69, 217–222 (2002).
   PubMed Web of Science ®Google Scholar
• Grassi C, Salvatori E, Martini A, Dionisio P. Evaluation of efficacy and tolerability of prulifloxacin versus amoxi-clavulanic acid in the treatment of acute exacerbations of chronic bronchitis. Angelini Ricerche SPA, Rome, Italy, May 27 (1998) (Data on file).
   Google Scholar
• Roveta S, Schito AM, Marchese A, Schito GC. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 26(5), 366–372 (2005).
   Google Scholar